# Comparison of Intravitreal Bevacizumab Injection with Combination of Suprachoroidal Triamcinolone Acetonide Along with Intravitreal Bevacizumab Injection in the Treatment of Diabetic Macular Edema in Pseudophakic Patients

> **NCT06882551** · PHASE4 · COMPLETED · sponsor: **Khyber Teaching Hospital** · enrollment: 82 (actual)

## Conditions studied

- Diabetic Macular Edema (DME)

## Interventions

- **DRUG:** Intravitreal Bevacizumab IVB
- **DRUG:** intravitreal bevacizumab and suprachoroidal triamcinolone acetonide

## Key facts

- **NCT ID:** NCT06882551
- **Lead sponsor:** Khyber Teaching Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-04-01
- **Primary completion:** 2023-11-30
- **Final completion:** 2024-01-15
- **Target enrollment:** 82 (ACTUAL)
- **Last updated:** 2025-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06882551

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06882551, "Comparison of Intravitreal Bevacizumab Injection with Combination of Suprachoroidal Triamcinolone Acetonide Along with Intravitreal Bevacizumab Injection in the Treatment of Diabetic Macular Edema in Pseudophakic Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06882551. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*